Telix Pharmaceuticals

Telix Pharmaceuticals Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Telix Pharmaceuticals (TLX.AX) as of Nov 22, 2026 is -4.44. In the previous year, Net Debt to Free Cash Flow Ratio was 25.85 — a change of -117.17% (lower).

Net Debt/FCF

-4.44

YoY

-117.17%

Last updated:

Net Debt to Free Cash Flow Ratio of Telix Pharmaceuticals is 2025 -4.44 . Net Debt to Free Cash Flow Ratio of Telix Pharmaceuticals was 2024 25.85 . It decreases by -117.17% lower compared to the previous year.

The Telix Pharmaceuticals Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
1.16 USD
Jan 1, 2019
1.78 USD
Jan 1, 2020
-46.24 USD
Jan 1, 2021
0.32 USD
Jan 1, 2022
1.36 USD
Jan 1, 2023
-10.05 USD
Jan 1, 2024
25.85 USD
Jan 1, 2025
-4.44 USD
The Telix Pharmaceuticals Net Debt/FCF history
YEARNet Debt/FCFYoY
-4.44-117.17%
25.85-357.05%
-10.05-839.08%
1.36+323.29%
0.32-100.70%
-46.24-2,691.45%
1.78+53.98%
1.16-85.55%
8.02—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telix Pharmaceuticals stock

Net Debt to Free Cash Flow Ratio of Telix Pharmaceuticals is -4.44 in 2025.

Net Debt to Free Cash Flow Ratio of Telix Pharmaceuticals changed from 25.85 to -4.44, representing a -117.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Telix Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals